BioNTech Announces Offer to Acquire CureVac
BioNTech SE has announced its intention to acquire certain interests related to CureVac. The completion of the offer is subject to various closing conditions, and the anticipated timetable may be affected by factors beyond their control. There are no guarantees that the necessary conditions will be met as expected, and actual outcomes may differ from current projections.
BioNTech SE and CureVac have provided an update on their previously announced transaction, which involves BioNTech’s intention to acquire certain interests related to CureVac. The companies stated that the completion of the offer and related transactions remains subject to various closing conditions, and that the anticipated timetable for completion may be affected by factors beyond their control. Both BioNTech and CureVac emphasized that there are no guarantees the necessary conditions will be met as expected, and actual outcomes may differ from current projections. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001141100-en) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
